logo
Second wave of flu sends hospitalizations surging; vaccines urged

Second wave of flu sends hospitalizations surging; vaccines urged

Yahoo12-02-2025
WINDBER, Pa. – A surge in flu-related hospitalization across western Pennsylvania – the highest statewide since 2010 – has some health centers reintroducing mask mandates.
Others, including officials at Chan Soon-Shiong Medical Center, urged the public to consider flu vaccinations, especially for the young and very old who are at higher risk for complications.
Dr. David Csikos, who serves as chief medical officer at the Windber-based medical center, said the rising caseload is particularly concerning for people already dealing with chronic issues – such as diabetes, heart disease and lung issues.
Dr. David Csikos
Dr. David Csikos
'That's where the risk is greatest. That's where we're seeing a lot of our cases,' Csikos said, noting the influenza's respiratory symptoms have a more severe impact on people who already have compromised health.
His advice: It's not too late to get vaccinated.
'The vaccines are safe and effective,' he said, noting they work to prevent severe complications from developing with the virus.
Csikos said the virus spreads annually in the colder months, and he continues advising people to get flu shots until late March.
Mandates issued
Several eastern Pennsylvania hospitals were operating under masking mandates for patients, visitors and staff, including University of Pennsylvania Health System in Philadelphia.
UPMC's Western Maryland facilities were also under a mask mandate this week, but that did not apply to health centers in Pennsylvania, hospital officials said.
UPMC Hillman Cancer Center at John P. Murtha Pavillion
Dr. Michael Voloshin, UPMC Hillman Cancer Center at John P. Murtha Pavillion medical oncologist, shown here at the facility on Somerset Street in downtown Johnstown on Wednesday, September 7, 2022.
Still, UPMC hospitals issued a statement 'strongly encouraging' masking inside all of its facilities.
'UPMC is seeing an increase in cases of respiratory viruses, including (COVID-19), influenza and RSV. To protect the health and safety of our employees, patients and visitors, everyone in our health care facilities is strongly encouraged to wear effective masks, which reduce transmission of respiratory viruses in health care settings,' UPMC officials said in a statement sent to The Tribune-Democrat.
UPMC has hospitals in Pittsburgh, Bedford, Altoona and Somerset, as well as its Johnstown-based cancer center, among others.
Flu cases surge
The Department of Health's respiratory virus dashboard showed influenza cases surging this month.
Cambria County's caseload rate was the highest in the region, with 1,234 cases reported for every 100,000 people.
Nearby Somerset County had a rate of 264 per 100,000, Department of Health figures showed.
RSV cases have also been high, but are declining statewide, while emergency visits for COVID cases are low statewide, CDC data indicates.
Conemaugh Memorial Medical Center officials confirmed both COVID and flu cases were up in February, but 'not beyond levels we would expect this time of year,' Marketing and Communications Director Tammy Barbin said.
She said hospital officials were monitoring the situation, and that masking remained voluntary as of Tuesday.
'Waning immunity'
Health officials noted the statewide trend was particularly alarming for children 4 years old and younger.
Just over 5.3% of the Southwest Region's emergency room visits were due to influenza cases.
Within the same southwest corridor of Pennsylvania, confirmed cases almost doubled, from just over 1,700 in mid-January to 3,030 Feb. 1, data show.
Csikos said a decline in vaccinations this flu season is likely playing a role.
For example, CDC figures show the percentage of children who are vaccinated this season was down to less than 45%, compared to almost 60% in 2019.
'There's a waning immunity level (across the nation),' he said.
Csikos said Windber medical officials are also monitoring cases locally and will consider reimplementing masking procedures inside its facilities if caseloads continue to climb.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Alloy Therapeutics and Kansai Startup Academia Coalition (KSAC) Announce Strategic Collaboration to Accelerate Global Growth of Japanese Life Science Startups
Alloy Therapeutics and Kansai Startup Academia Coalition (KSAC) Announce Strategic Collaboration to Accelerate Global Growth of Japanese Life Science Startups

Business Wire

timean hour ago

  • Business Wire

Alloy Therapeutics and Kansai Startup Academia Coalition (KSAC) Announce Strategic Collaboration to Accelerate Global Growth of Japanese Life Science Startups

BOSTON & TOKYO--(BUSINESS WIRE)--Alloy Therapeutics Co. Ltd. ('Alloy Japan') today announced the signing of a Memorandum of Understanding (MOU) with the Kansai Startup Academia Coalition ('KSAC'), represented by Kyoto University, to foster the global expansion of university-affiliated life science startups across Japan. This strategic collaboration is designed to accelerate research and development (R&D) activities by providing critical support and connecting academic innovations with the global biopharmaceutical industry. KSAC is a coalition of more than 90 academic institutions located in western Japan, formed under the leadership of Kyoto University and with support from Japan's Ministry of Education, Culture, Sports, Science and Technology (MEXT). KSAC's mission is to bridge academia and industry by managing GAP funds for research, delivering entrepreneurship education, supporting digital workshop networks, and showcasing early-stage technologies through events and exhibitions both domestically and internationally. Alloy Therapeutics Inc. ('Alloy') is a Boston-based biotechnology ecosystem company that democratizes access to foundational biologics discovery technologies. Through its suite of platform technologies and discovery services as well as its venture studio, 82VS, Alloy enables scientists and entrepreneurs around the world to accelerate the discovery of medicines. Alloy recently launched its Japan subsidiary, Alloy Japan, which is focused on iPS cell therapy development and is continuing to broaden its offerings by supporting ecosystem growth throughout Japan and greater Asia. Through this MOU, Alloy Japan and KSAC will collaborate to connect promising academic seeds from Japan to global Biopharma markets, while also bringing valuable insights from the global community back to strengthen Japan's startup ecosystem. Together, they aim to enrich critical capabilities across Japan's academic and entrepreneurial communities to foster the development of globally competitive life science startups. 'Alloy's capabilities and global network bring a highly complementary strength to our mission of empowering academic startups to compete internationally. Alloy Japan offers a highly distinct and complementary contribution to our activities with Global Incubators and Venture Capital firms,' said Koji Murota, Director-General of the Office of Institutional Advancement and Communications at Kyoto University, representing KSAC. 'By collaborating with ecosystem builders like Alloy Japan, we can provide our researchers and entrepreneurs with access to additional scientific resources, global Biopharma insights, and opportunities to scale their innovations beyond Japan.' As a first step, Alloy Japan will support KSAC's GAP Fund program, which provides funding to selected academic projects within the KSAC network. Over the three-year term of the MOU, the collaboration is expected to expand to additional KSAC initiatives aimed at building a globally integrated and innovation-driven biotech community. 'Our collaboration with KSAC builds on Alloy Japan's commitment to deep, sovereign partnerships that nurture innovation at the academic and early translational stages,' said Victor Stone (Yoshihide Ishii), CEO of Alloy Japan. 'By working alongside KSAC and its network of universities, we aim to strengthen the bridge between Japanese academic excellence and the Biopharma ecosystem, accelerating the global growth of life science startups.' About Alloy Therapeutics Inc. Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners across academia, biotech, and the largest biopharma, Alloy democratizes access to pre-competitive tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics across six modalities: antibodies, TCRs, genetic medicines, peptides, cell therapies, and drug delivery. As a reflection of Alloy's relentless commitment to the scientific community, Alloy reinvests 100% of its revenue in innovation and access to innovation. Headquartered in Boston, MA, Alloy operates globally with discovery laboratories in multiple locations, including Japan. Its Japanese subsidiary, Alloy Japan, located at Shonan Health Innovation Park in Kanagawa Prefecture and led by Victor Stone (Yoshihide Ishii), supports cell therapy initiatives and broader ecosystem activities in the region. Join the Alloy Therapeutics ® community by visiting and following Alloy on LinkedIn. About KSAC & Kyoto University The Kansai Startup Academia Coalition (KSAC), led by leading research institution Kyoto University, is a nationwide initiative dedicated to promoting the internationalization and growth of startups originating from Japanese universities.

3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results
3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results

Yahoo

time3 hours ago

  • Yahoo

3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results

Key Points Eli Lilly, Summit Therapeutics, and Vertex Pharmaceuticals all have important ongoing clinical trials. Shares of these drugmakers could jump if the data from the studies is positive. All three companies have attractive prospects beyond that. 10 stocks we like better than Eli Lilly › Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, long-term investors should have a balanced approach to potentially positive data readouts. Putting aside the fact that it's impossible to predict the outcome of a clinical trial beforehand, even when the results are up to Wall Street's standards, it's hardly worth investing in the company unless there are other good reasons to think it will perform well over long periods. That's why you may want to take a closer look at Eli Lilly (NYSE: LLY), Summit Therapeutics (NASDAQ: SMMT), and Vertex Pharmaceuticals (NASDAQ: VRTX). All three drugmakers should release results from key clinical trials within the next 18 months, and all three have strong prospects for the next five years at least. 1. Eli Lilly In April, Eli Lilly reported positive phase 3 results for its oral GLP-1 candidate, orforglipron. While the market reacted positively to this development, the study in question focused on diabetes patients and used A1c reduction as its primary endpoint. All eyes will be on the company's ongoing late-stage studies for orforglipron in obesity; it should release data from at least one of those clinical trials within the next year. Eli Lilly's work in weight management has taken center stage in the past few years. The pharmaceutical leader could, once again, make a breakthrough by being one of the first to launch a highly effective oral GLP-1 anti-obesity drug. Since current options are administered subcutaneously, you can expect orforglipron to reach a reasonable level of success on the market -- but that's only if it performs well in phase 3 obesity studies. If it fails to do so, Lilly's shares could plunge. Even so, the stock should still be a buy. True, orforglipron would strengthen Lilly's already robust lineup. But even if it falls short of expectations in late-stage studies, the company has several other candidates in development, including retatrutide, which is also in phase 3 trials. Meanwhile, Lilly continues to generate consistent financial results. Revenue and earnings have been growing at a good clip, and that should continue for the foreseeable future. Lastly, Eli Lilly is an excellent dividend growth stock. Although results from phase 3 trials for orforglipron in obesity will be important to monitor, the stock should perform well over the long run, regardless of the outcome of these trials. 2. Summit Therapeutics Summit Therapeutics is developing ivonescimab, a cancer medicine it licensed from Akeso, a China-based biopharma. Ivonescimab is already approved in China; however, Summit needs to conduct clinical trials elsewhere to support approval in the U.S., Europe, and other regions where it holds marketing rights. At least one of these studies will be of particular interest to investors. Summit is testing its crown jewel in a late-stage trial against Merck's Keytruda in patients with non-small cell lung cancer (NSCLC), in a study called Harmoni-3. Enrollment in the study is ongoing, and there is a good chance we'll see top-line data from it by the end of next year. Summit's stock soared when it reported that ivonescimab did better than Keytruda at reducing the risk of recurrence or death in NSCLC patients, in a study conducted in China. However, reproducing this result elsewhere could, once again, jolt the stock price. On the flip side, Summit's share price will move in the wrong direction if the results aren't what Wall Street expects. Should you buy the stock? To me, Summit Therapeutics' prospects for the next five years seem attractive. Ivonescimab is being tested across a range of different cancers, and it looks highly promising in NSCLC, which could be its most important market. Even with the possibility that it may not perform as well in studies outside of China, having already been approved by regulatory authorities in one region reduces the risk of significant clinical and regulatory setbacks. Ivonescimab looks like a potential pipeline in a drug. And if you invest in Summit Therapeutics now, you might reap the benefits of its leading candidate's potential. 3. Vertex Pharmaceuticals Vertex Pharmaceuticals is a proven innovator. The company's strategy is to develop breakthrough medicines where there's a high unmet need. One of Vertex's new targets is type 1 diabetes (T1D). There are no cures for this chronic disease, but the biotech's candidate zimislecel could be a functional cure, in the sense that it could recover patients' ability to produce their own insulin -- something that people with T1D can't do. In the phase 1/2 portion of an ongoing phase 1/2/3 clinical trial, 10 of 12 patients who received zimislecel were insulin-free after a one-year follow-up. All 12 were free of severe hypoglycemic events after 90 days. Vertex should have data from the late-stage portion of this ongoing clinical trial within the next year. Positive results will be well received. The company also aims to submit regulatory applications for this product sometime in 2026. Zimislecel should be a nice addition to Vertex's portfolio. The biotech remains the leader in the market for drugs that treat the underlying genetic causes of cystic fibrosis, a business that is still helping it drive strong revenue and earnings growth. Furthermore, Vertex has added several medicines to its portfolio over the past five years, including Journavx for acute pain and Casgevy for two rare blood-related disorders. Vertex Pharmaceuticals' pipeline also has promising programs beyond zimislecel. Well beyond the announcement of clinical-trial results for this promising T1D therapy, the stock will be in an excellent position to perform. Should you buy stock in Eli Lilly right now? Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Prosper Junior Bakiny has positions in Eli Lilly and Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Merck, Summit Therapeutics, and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. 3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results
3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results

Yahoo

time3 hours ago

  • Yahoo

3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results

Key Points Eli Lilly, Summit Therapeutics, and Vertex Pharmaceuticals all have important ongoing clinical trials. Shares of these drugmakers could jump if the data from the studies is positive. All three companies have attractive prospects beyond that. 10 stocks we like better than Eli Lilly › Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, long-term investors should have a balanced approach to potentially positive data readouts. Putting aside the fact that it's impossible to predict the outcome of a clinical trial beforehand, even when the results are up to Wall Street's standards, it's hardly worth investing in the company unless there are other good reasons to think it will perform well over long periods. That's why you may want to take a closer look at Eli Lilly (NYSE: LLY), Summit Therapeutics (NASDAQ: SMMT), and Vertex Pharmaceuticals (NASDAQ: VRTX). All three drugmakers should release results from key clinical trials within the next 18 months, and all three have strong prospects for the next five years at least. 1. Eli Lilly In April, Eli Lilly reported positive phase 3 results for its oral GLP-1 candidate, orforglipron. While the market reacted positively to this development, the study in question focused on diabetes patients and used A1c reduction as its primary endpoint. All eyes will be on the company's ongoing late-stage studies for orforglipron in obesity; it should release data from at least one of those clinical trials within the next year. Eli Lilly's work in weight management has taken center stage in the past few years. The pharmaceutical leader could, once again, make a breakthrough by being one of the first to launch a highly effective oral GLP-1 anti-obesity drug. Since current options are administered subcutaneously, you can expect orforglipron to reach a reasonable level of success on the market -- but that's only if it performs well in phase 3 obesity studies. If it fails to do so, Lilly's shares could plunge. Even so, the stock should still be a buy. True, orforglipron would strengthen Lilly's already robust lineup. But even if it falls short of expectations in late-stage studies, the company has several other candidates in development, including retatrutide, which is also in phase 3 trials. Meanwhile, Lilly continues to generate consistent financial results. Revenue and earnings have been growing at a good clip, and that should continue for the foreseeable future. Lastly, Eli Lilly is an excellent dividend growth stock. Although results from phase 3 trials for orforglipron in obesity will be important to monitor, the stock should perform well over the long run, regardless of the outcome of these trials. 2. Summit Therapeutics Summit Therapeutics is developing ivonescimab, a cancer medicine it licensed from Akeso, a China-based biopharma. Ivonescimab is already approved in China; however, Summit needs to conduct clinical trials elsewhere to support approval in the U.S., Europe, and other regions where it holds marketing rights. At least one of these studies will be of particular interest to investors. Summit is testing its crown jewel in a late-stage trial against Merck's Keytruda in patients with non-small cell lung cancer (NSCLC), in a study called Harmoni-3. Enrollment in the study is ongoing, and there is a good chance we'll see top-line data from it by the end of next year. Summit's stock soared when it reported that ivonescimab did better than Keytruda at reducing the risk of recurrence or death in NSCLC patients, in a study conducted in China. However, reproducing this result elsewhere could, once again, jolt the stock price. On the flip side, Summit's share price will move in the wrong direction if the results aren't what Wall Street expects. Should you buy the stock? To me, Summit Therapeutics' prospects for the next five years seem attractive. Ivonescimab is being tested across a range of different cancers, and it looks highly promising in NSCLC, which could be its most important market. Even with the possibility that it may not perform as well in studies outside of China, having already been approved by regulatory authorities in one region reduces the risk of significant clinical and regulatory setbacks. Ivonescimab looks like a potential pipeline in a drug. And if you invest in Summit Therapeutics now, you might reap the benefits of its leading candidate's potential. 3. Vertex Pharmaceuticals Vertex Pharmaceuticals is a proven innovator. The company's strategy is to develop breakthrough medicines where there's a high unmet need. One of Vertex's new targets is type 1 diabetes (T1D). There are no cures for this chronic disease, but the biotech's candidate zimislecel could be a functional cure, in the sense that it could recover patients' ability to produce their own insulin -- something that people with T1D can't do. In the phase 1/2 portion of an ongoing phase 1/2/3 clinical trial, 10 of 12 patients who received zimislecel were insulin-free after a one-year follow-up. All 12 were free of severe hypoglycemic events after 90 days. Vertex should have data from the late-stage portion of this ongoing clinical trial within the next year. Positive results will be well received. The company also aims to submit regulatory applications for this product sometime in 2026. Zimislecel should be a nice addition to Vertex's portfolio. The biotech remains the leader in the market for drugs that treat the underlying genetic causes of cystic fibrosis, a business that is still helping it drive strong revenue and earnings growth. Furthermore, Vertex has added several medicines to its portfolio over the past five years, including Journavx for acute pain and Casgevy for two rare blood-related disorders. Vertex Pharmaceuticals' pipeline also has promising programs beyond zimislecel. Well beyond the announcement of clinical-trial results for this promising T1D therapy, the stock will be in an excellent position to perform. Should you buy stock in Eli Lilly right now? Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Prosper Junior Bakiny has positions in Eli Lilly and Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Merck, Summit Therapeutics, and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. 3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store